The quest for Eldorado: Development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain

Current Pharmaceutical Design

Volumn 12, Issue 30, 2006, Pages 3877-3900

  Horti, Andrew G ^a   Villemagne, Victor L ^b,c,d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b AUSTIN HOSPITAL   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

BBB transport; Brain receptor density; Neurodegenerative diseases; PET labeled epibatidine; Positron emission tomography (PET)

Indexed keywords

3 (2 AZETIDINYLMETHOXY)PYRIDINE; 6 CHLORO 3 [(2 AZETIDINYL)METHOXY] 5 (2 FLUOROPYRIDIN 4 YL)PYRIDINE COLLOID F 18; 6 CHLORO 3 [(2 AZETIDINYL)METHOXY] 5 (6 FLUOROPYRIDIN 3 YL)PYRIDINE COLLOID F 18; 6 CHLORO 3 [(2 AZETIDINYL)METHOXY] 5 [2 (2 FLUOROPYRIDIN 4 YL)VINYL]PYRIDINE COLLOID F 18; 9 (2 FLUOROPYRIDINYL)CYTISINE COLLOID F 18; A 186253; A 84543; A 85865; ACETYLCHOLINE; ALPHA BUNGAROTOXIN I 125; BRAIN RECEPTOR; CHOLINERGIC RECEPTOR; CYTISINE; EPIBATIDINE; IODINE 123; ISOFLURANE; KETAMINE; METANICOTINE C 11; NICOTINE C 11; NICOTINE PATCH; NICOTINIC AGENT; NICOTINIC RECEPTOR; NIDA 52158; NIDA 52189; NIDA 522131; NIDA 52289; NIFROLIDINE COLLOID F 18; NIFZETIDINE COLLOID F 18; RACLOPRIDE; RADIOLIGAND; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; XYLAZINE;

ALZHEIMER DISEASE; ANXIETY DISORDER; BINDING KINETICS; DEGENERATIVE DISEASE; DEPRESSION; DRUG BINDING SITE; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME KINETICS; EPILEPSY; GILLES DE LA TOURETTE SYNDROME; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; LIPOPHILICITY; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RADIOCHEMISTRY; RELIABILITY; REVIEW; SCHIZOPHRENIA; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING CESSATION; THALAMUS; TOBACCO DEPENDENCE;

ANIMALS; BRAIN; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RECEPTORS, NICOTINIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33749863936     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778559605     Document Type: Review

References (160)

1. Deneris ES, Connolly J, Rogers SW, Duvoisin R. Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors. Trends Pharmacol Sci 1991; 12: 34-40:
2. Lindstrom J, Anand R, Peng X, Gerzanich V, Wang F, Li Y. Neuronal nicotinic receptor subtypes. Ann N Y Acad Sci 1995; 757: 100-16.
3. Lukas RJ, Changeux JP, Le Novere N, Albuquerque EX, Balfour DJ, Berg DY, et al. International Union of Pharmacology. XX Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 1999; 51: 397-401.
4. Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain. Prog Neurobiol 2000; 61: 75-111.
5. Decker MW, Brioni JD, Bannon AW, Americ SP. Diversity of neuronal niotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics. Life Sci 1995; 56: 545-70.
6. Tassonyi E, Charpantier E, Muller D, Dumont L, Bertrand D. The role of nicotinic acetylcholine receptors in the mechanisms of anesthesia. Brain Res Bull 2002; 57: 133-50.
7. 3H]Cytisine binding to nicotinic cholinergic receptors in brain. Mol Pharmacol 1991; 39: 9-12.
8. 3H]epibatidine. Brain Res 1998; 801: 143-9.
9. 3H]epibatidine in vitro autoradiography. Neuroscience 1998; 85: 1121-33.
10. 125I]a-bungarotoxin. J Neurosci 1985; 5: 1307-15.
11. Holladay MW, Dart MJ, Lynch JK. Neuronal nicotinic acetylcho line receptors as targets for drug discovery. J Med Chem 1997; 40: 4169-94.
12. Nordberg A, Adem A, Hardy J, Winblad B. Change in nicotinic receptor subtypes in temporal cortex of Alzheimer brains. Neurosci Lett 1988; 86: 317-21.
13. Whitehouse PJ, Kellar KJ. Nicotinic and muscarinic cholinergic receptors in Alzheimer's disease and related disorders. J Neural Transm Suppl 1987; 24: 175-82.
14. Whitehouse PJ, Martino AM, Marcus KA, Zweig RM, Singer HS, Price DL, et al. Reductions in acetylcholine and nicotine binding in several degenerative diseases. Arch Neurol 1988; 45: 722-4.
15. Whitehouse PJ, Kalaria RN. Nicotinic receptors and neurodegenerative dementing diseases: basic research and clinical implications. Alzheimer Dis Assoc Disord 1995; 9(Suppl 2): 3-5.
16. Warpman U, Nordberg A. Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. Neuroreport 1995; 6: 2419-23.
17. 3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci Lett 1986; 72: 115-9.
18. 3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study. Neurology 1988a 38: 720-3.
19. Kellar KJ, Whitehouse PJ, Martino-Barrows AM, Marcus K, Price DL. Muscarinic and nicotinic cholinergic binding sites in Alzheimer's disease cerebral cortex. Brain Res 1987; 436: 62-8.
20. London ED, Ball MJ, Waller SB. Nicotinic binding sites in cerebral cortex and hippocampus in Alzheimer's dementia. Neurochem Res 1989; 14: 745-50.
21. Court J, Clementi F. Distribution of nicotinic subtypes in human brain. Alzheimer Dis Assoc Disord 1995; 9(Suppl 2): 6-14.
22. Bunnelle WH, Dart MJ, Schrimpf MR. Design of ligands for the nicotinic acetylcholine receptors: The quest for selectivity. J Med Chem 2004; 4: 299-334.
23. Abreo MA, Lin NH, Garvey DS, Gunn DE, Hettinger AM, Wasicak JT, et al. Novel 3-Pyridyl Ethers with Subnanomolar Affinity for Central Neuronal Nicotinic Acetylcholine Receptors. J Med Chem 1996; 39: 817-25.
24. Farde L. The advantage of using positron emission tomography in drug research. Trends Neurosci 1996; 19: 211-4.
25. Bergstrom M, Grahnen A, Langstrom B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 2003; 59: 357-66.
26. Farde L, Nordstrom AL. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry Suppl 1992; 160: 30-3.
27. Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996; 153: 948-50.
28. Roemer RA, Richelson E, Shagass C, Leventhal L. A method to estimate in vivo D2 receptor occupancy by antipsychotic drugs. J Psychiatry Neurosci 1996; 21: 325-33.
29. Corrigall WA, Franklin KBJ, Coen KM, Clarke PBS. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 1992; 107: 285-9.
30. Henningfield JE, Woodson PP. Behavioral and physiologic aspects of nicotine dependence: the role of nicotine dose. Prog Brain Res 1989; 79: 303-12.
31. Balfour DJ, Fagerstrom KO. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders Pharmacol Ther 1996; 72:51-81.
32. Williams M, Sullivan JP, Americ SP. Neuronal nicotinic acetyl choline receptors. Drug News Perspect 1994; 7: 205-223.
33. 3[H]nicotine binding sites in human brain. J Neurochem 1988; 50: 1243-7.
34. 3H]nicotine binding in human postmortem brain. J Pharmacol Exp Ther 1997; 282: 7-13.
35. Marks MJ, Stitzel JA, Collins AC. Time course study of the effects of chronic nicotine infusion on drug response and brain receptors. J Pharmacol Exp Ther 1985; 235: 619-28.
36. Pauly JR, Marks MJ, Gross SD, Collins AC. An autoradiographic analysis of cholinergic receptors in mouse brain after chronic nicotine treatment. J Pharmacol Exp Ther 1991; 258: 1127-36.
37. Wonnacott S. The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends Pharmacol Sci 1990; 11: 216-9.
38. Yates SL, Bencherif M, Fluhler EN, Lippiello PM. Up-regulation of nicotinic acetylcholine receptors following chronic exposure of rats to mainstream cigarette smoke or alpha 4 beta 2 receptors to nicotine. Biochem Pharmacol 1995, 50: 2001-8.
39. Halldin C, Gulyas B, Farde L. PET studies with carbon-11 radioligands in neuropsychopharmacological drug development. Cur Pharm Des 2001; 7: 1907-21.
40. Dannals RF RH, Wilson AA. In: Burns HD, Dannals RF, Siegl PKS, ed. Chemistry of tracers for positron emission tomography. Nuclear imaging in drug discovery, development, and approval, Birkhäuser: Boston 1993; 55-74.
41. de Paulis T. The discovery of epidepride and its analogs as high-affinity radioligands for imaging extrastriatal dopamine D2 receptors in human brain. Curr Pharm Des 2003; 9: 673-96.
42. Laruelle M, Slifstein M, Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mel Imaging Biol 2003; 5: 363-75.
43. Fadda P, Martellotta MC, Gessa GL, Fratta W. Dopamine and opioids interactions in sleep deprivation. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17: 269-78.
44. 3H]spiperone. Mol Pharmacol 2003; 63: 456-62.
45. 125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors. Life Sci 1991; 49: 617-28.
46. Pohjalainen T, Rinne JO, Nagren K, SyvAlahti E, Hietala J. Sex Differences in the Striatal Dopamine D2 Receptor Binding Characteristics in vivo. Am J Psychiatry 1998; 155: 768-73.
47. 3H]haloperidol in human and rat cerebellum. Naunyn Schmiedebergs Arch Pharmakol 1992; 345: 197-202.
48. Sanabria-Bohorquez SM, De Volder AG, Arno P, Sibomana M, Coppens A, et al. Decreased benzodiazepine receptor density in the cerebellum of early blind human subjects. Brain Res 2001; 888: 203-211.
49. 3H]cytisine binding to human brain membrane preparations. Brain Res 1993; 600: 127-33.
50. Hansch C, Clayton JM. Lipophilic character and biological activity of drugs. II. The parabolic case. J Pharm. Sci 1973; 62: 1-21.
51. Disbino DD, Welch MJ, Kilbourn MR, Raichle ME. Relationship between lipophilicity and brain extraction of carbon-11-labeled radiopharmaceuticals. J Nucl Med 1983; 24: 1030-8.
52. Welch MJ, Chi DY, Mathias CJ, Kilbourn MR, Brodack JW, Katzenellenbogen JA. Biodistribution of N-alkyl and N-fluoroalkyl derivatives of spiroperidol, radiopharmaceuticals for PET studies of dopamine receptors. Nucl Med Biol 1986; 13: 523-6.
53. Kubinyi H. In: Wolff ME, ed. The quantitative analysis of structure-activity relationships. Burger's Medicinal Chemistry and Drug Discovery. Wiley-Interscience, 1995; 497.
54. Zhang Y, Pavlova OA, Chefer SI, Hall AW, Kurian V, Brown LL, et al. 5-Substituted Derivatives of 6-Halogeno-3-((2-(S)-azetidinyl) methoxy)pyridine and 6-Halogeno-3-((2-(S)-pyrrobdinyl)methoxy) pyridine with Low Picomolar Affinity for a4b2 Nicotinic Acetylcholine Receptor and Wide Range of Lipophilicity: Potential Probes for Imaging with Positron Emission Tomography. J Med Chem 2004; 47: 2453-2465.
55. Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Piattoni-Kaplan M, et al. A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand. Neuropharmacology 1996; 35: 725-34.
56. Sihver W, Fasth KJ, Ogren M, Lundqvist H, Bergstrom M, Watanabe Y, et al. In vivo positron emission tomography studies on the novel nicotinic receptor agonist [11C]MPA compared with [11C] ABT-418 and (S)(-)[11C]nicotine in rhesus monkeys. Nucl Med Biol 1999; 26: 633-40.
57. Muzic RF Jr, Berridge MS, Friedland RP, Zhu N, Nelson AD. PET quantification of specific binding of carbon-11-nicotine in human brain. J Nucl Med 1998; 39: 2048-54.
58. Gundisch D. Nicotinic acetylcholine receptors and imaging. Curr Pharm Des 2000; 6: 1143-57.
59. 18F]A-85380). J Labelled Comp Radiopharm 1998; 41: 309-318.
60. 18F]fluoro-3-[2(S)-2-azetidinylmethoxy] pyridine, a highly potent radioligand for in vivo imaging central nicotinic acetylcholine receptors. J Labelled Comp Radiopharm 1998; 41: 451-463.
61. Brown LL, Kulkarni S, Pavlova OA, Koren AO, Mukhin AG, Newman AH, et al. Synthesis and Evaluation of a Novel Series of 2-Chloro-5- 1-methyl-2-(S)-pyrrolidinyl]methoxy]-3-[2-(4-pyridinyl) vinyl]pyridine Analogs as Potential Positron Emission Tomography Imaging Agents for Nicotinic Acetylcholine Receptors. J Med Chem 2002; 45: 2841-2849.
62. 18F]FA binding to nicotinic acetylcholine receptors in rhesus monkey brain. Synapse 2003; 48: 25-34.
63. 18F-fluoro-A-85380 in healthy volunteers. J Nucl Med 2003; 44: 596-601.
64. 18F]fluoro-A-85380, a novel radioligand for in vivo imaging of central nicotinic acetylcholine receptors. Life Sci 2000; 67: 463-9.
65. 18F]Fluoro-3-(2(S)-azetidinylmethoxy)pyridine, a high-affinity radioligand for central nicotinic acetylcholine receptors. J Labelled Comp Radiopharm 2000; 43: 413-423.
66. 18F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine as a PET tracer for nicotinic acetylcholine receptors. Nucl Med Biol 2000; 27: 381-9.
67. 18F]fluoro-A-85380, a high-affinity ligand for alpha4beta2* nicotinic acetylcholine receptors. Synapse 2005; 55: 89-97.
68. 18F]Fluoro-A-85380, a new PET tracer for the nicotinic acetylcholine receptor: studies in the human brain and in vivo demonstration of specific binding in white matter. Synapse 2004; 53: 184-9.
69. 123/125I] iodo-3-(2(S)-azetidinylmethoxy)pyridine: a radioligand for nicotinic acetylcholine receptors. Nucl Med Biol 1999; 26: 175-182.
70. Musachio JL, Villemagne VL, Scheffel UA, Dannals RF, Dogan AS, Yokoi F, et al. Synthesis of an 1-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon. Nucl Med Biol 1999; 26: 201-7.
71. 23I]iodo-A-85380 using single photon emission computed tomography. Life Sci 1998; 63: L355-60.
72. 123I]5-J-A-85380 SPET. Eur J Nucl Med Mol Imaging 2003; 30: 1620-9.
73. Villemagne VL, Musachio JL, Scheffel U. In: Arneric SP, Brioni JD, ed. Nicotine and related compounds as PET and SPECT ligands. Neuronal Nicotinic Receptors, Pharmacology and Therapeutic Opportunities. New York, John Wiley & Sons 1999; 235-250.
74. Sihver W, Langstrom B, Nordberg A. Ligands for in vivo imaging of nicotinic receptor subtypes in Alzheimer brain. Acta Neurol Scand Suppl 2000; 176: 27-33.
75. Sihver W, Nordberg A, Langstrom B, Mukhin AG, Koren AO, Kimes AS, et al. Development of ligands for in vivo imaging of cerebral nicotinic receptors. Behav Brain Res 2000; 113: 143-57.
76. Volkow ND, Ding YS, Fowler JS, Gatley SJ. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. Biol Psychiatry 2001; 49: 211-20.
77. 11C]Methylated Analogs of Epibatidine as Tracers for Positron Emission Tomographic Studies of Nicotinic Acetylcholine Receptors. J Med Chem 1998; 41: 4199-4206.
78. 18F]fluoro-A-85380, an in vivo tracer for the nicotinic acetylcholine receptors. Nucl Med Biol 1998; 25: 599-603.
79. Vaupel DB, Tella SR, Huso DL, Wagner VO, Mukhin AG, Chefer SI, Horti AG, et al. Pharmacological and toxicological evaluation of 2-fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-F-A-85380), a ligand for imaging cerebral nicotinic acetylcholine receptors with positron emission tomography. J Pharmacol Exp Ther 2005; 312: 355-65.
80. 123I]5-I-A-85380, a radioligand for in vivo imaging of cerebral neuronal nicotinic acetylcholine receptors in humans. Drug Dev Res 2003; 58: 149-168.
81. 123I]5-I-A-85380 in healthy human subjects. Eur J Nucl Med Mol Imaging 2002; 29: 183-90.
82. 18F]fluoro-A-85380. J Nucl Med 1999; 40: 1374-80.
83. 18F]F-A85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. FASEB J 2003; 17: 1331-3.
84. 123I]Iodo-A-85380: assessment of pharmacological safety, radiation dosimetry and SPECT imaging of brain nicotinic receptors in healthy human subjects. Ann Nucl Med 2004; 18: 337-44.
85. 125I]-A-85380. Neuropsychopharmacology 2004; 29: 108-16.
86. Kulak JM, Sum J, Musachio JL, McIntosh JM, Quik M. 5-Iodo-A-85380 binds to alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors (nAChRs) as well as alpha4beta2* subtypes. J Neurochem 2002; 81: 403-6.
87. Kassiou M, Eberl S, Meikle SR, Birrell A, Constable C, Fulham MJ, et al. In vivo imaging of nicotinic receptor upregulation following chronic (-)-nicotine treatment in baboon using SPECT. Nucl Med Biol 2001; 28: 165-75.
88. 123I] iodo-3-(2-azetidinylmethoxy)pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in nonhuman primates. Nucl Med Biol 2001; 28: 91-6.
89. 123I]5-I-A-85380. Synapse 2003; 48: 116-22.
90. 123I]5-I-A-85380 Dynamic SPECT Studies in Normals: Kinetic Analysis and Parametric Imaging, Proc IEEE Nucl Sci Symposium and Med Imaging, Norfolk, Virginia 2001; 1335-1340.
91. 123I-5IA SPECT. J Nucl Med 2004; 45: 1458-70.
92. 18F]F-A-85380: a PET radioligand for alpha4beta2 nicotinic acetylcholine receptors. Neuroreport 1999; 10: 2715-21.
93. 18F]fluoro-A-85380: A PET study in monkeys. Synapse 2002; 44: 58-9.
94. 18F-Fluoro-A-85380 and PET. J Nucl Med 2005; 46: 240-247.
95. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834-40.
96. Koren AO, Horti AG, Mukhin AG, Guendisch D, Kimes AS, Dannals RF, et al. 2-,5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: Synthesis, Affinity for Nicotinic Acetylcholine Receptors, and Molecular Modeling. J Med Chem 1998; 41: 3690-8.
97. 18F]Fluoro-A-85380: an in vivo tracer for the nicotinic acetylcholine receptor. Nucl Med Biol 2000; 27: 51-6.
98. Pimlott SL, Piggott M, Owens J, Greally E, Court JA, Jaros E, et al. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[125I]-α-85380. Neuropsychopharmacology 2004; 29: 108-16.
99. Gahring LC, Persiyanov K, Dunn D, Weiss R, Meyer EL, Rogers SW. Mouse strain-specific nicotinic acetylcholine receptor expression by inhibitory interneurons and astrocytes in the dorsal hippocampus. J Comp Neurol 2004; 468: 334-46.
100. Brown L, Chefer S, Pavlova O, Vaupel DB, Koren AO, Kimes AS, et al. Evaluation of 5-(2-(4-pyridinyl)vinyl)-6-chloro-3-(1-methyl-2-(S)- pyrrolidinylmethoxy)py ridine and its analogues as PET radioligands for imaging nicotinic acetylcholine receptors. J Neurochem 2004; 91: 600-12.
101. Brown LL, Pavlova O, Mukhin A, Kimes AS, Horti AG. Radiosynthesis of 5-[2-(4-pyridinyl)vinyl]-6-chloro-3-[(1-[11C]methyl-2-(S)- pyrrolidinyl)methoxy]pyridine, a high affinity ligand for studying nicotinic acetylcholine receptors by positron emission tomography. Bioorg Med Chem 2001; 9: 3055-3058.
102. Fan H, Scheffel UA, Rauseo P, Xiao Y, Dogan AS, Yokoi F, et al. [125/ 123I] 5-Iodo-3-pyridyl ethers. syntheses and binding to neuronal nicotinic acetylcholine receptors. Nucl Med Biol 2001; 28: 911-21.
103. Wevers A, Burghaus L, Moser N, Witter B, Steinlein OK, Schutz U, et al. Expression of nicotinic acetylcholine receptors in Alzheimer's disease: postmortem investigations and experimental approaches. Behav Brain Res 2000; 113: 207-15.
104. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000; 20: 423-51.
105. Henderson DJ, Eberl S, Thomson S, Smith A, Allan RD, Fulham MJ, et al. 3-Pyridyl ethers as SPECT radioligands for imaging nicotinic acetylcholine receptors. Appl Radiat Isot 2004; 60: 669-76.
106. Sihver W, Fasth KJ, Horti AG, Koren AO, Bergstrom M, Lu L, et al. Synthesis and characterization of binding of 5-[76Br]bromo-3- 2(S)-azetidinyl]methoxy]pyridine, a novel nicotinic acetylcholine receptor ligand, in rat brain. J Neurochem 1999; 73: 1264-1272.
107. Mukhin AG, Gundisch D, Horti AG, Koren AO, Tamagnan G, Kimes AS, et al. 5-Iodo-A-85380, an a4b2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol 2000; 57: 642-649.
108. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 2000; 25: 161-6.
109. Chikhale EG, Burton PS, Borchardt RT. The effect of verapamil on the transport of peptides across the blood-brain barrier in rats: kinetic evidence for an apically polarized efflux mechanism. J Pharmacol Exp Ther 1995; 273: 298-303.
110. Chikhale EG, Ng KY, Burton PS, Borchardt RT. Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain barrier permeability of peptides. Pharm Res 1994; 11: 412-19.
111. 18F]NIDA52158. Unpublished data, NIDA/IRP, NIH: 2004
112. Zhang Y, Mukhin AG, Pavlova OA, Chefer SI, Vaupel DB, Brown LL, et al. Synthesis, structure-activity relationship, and pre-evaluation of heteryl derivatives of A-85380 as potential radiotracers for imaging of nicotinic acetylcholine receptors in extrathalamic brain regions by positron emission tomography. Abstracts of Papers 225th ACS National Meeting, New Orleans, LA, United States, March 23-27 2003
113. Lin N-H, He Y, Holladay MW, Ryther K, Li Y. 3-Pyridyloxymethyl heterocyclic ether compounds useful as nicotinic cholinergic ligands in controlling chemical synaptic transmission. 1997, US Patent 5 629 325
114. 18F]-labelled fluoro derivative of (-)-cytisine as a candidate radioligand for brain nicotinic alpha4beta2 receptor imaging with PET. Bioorg Med Chem 2003; 11: 5333-43.
115. Itier V, Schonbachler R, Tribollet E, Honer M, Prinz K, Marguerat A, et al. A-186253, a specific antagonist of the alpha4beta2 nAChRs: its properties and potential to study brain nicotinic acetylcholine receptors. Neuropharmacology 2004; 47: 538-57.
116. 18F-Fluoropropyl)-3-(2-(S)- Pyrrolidinylmethoxy)Pyridine, in Rodents and PET in Nonhuman Primate. J Nucl Med 2005; 46: 130-140.
117. 18F]NIDA 522131), a novel potential radioligand for studying extrathalamic nicotinic acetylcholine receptors by PET. J Labelled Comp Radiopharm 2004; 47: 947-952.
118. 18F]NIDA 52289), a very high affinity radioligand for nicotinic acetylcholine receptors. J Labelled Comp Radiopharm 2004; 47: 385-392.
119. Chefer SI, Pavlova OA, Zhang Y, Vaupel DB, Kimes AS, Kurian V, et al. NIDA 522189 And NIDA 522131: New Promising Radioligands for PET Imaging Extrathalamic Nicotinic Receptors. The 15th International Symposium on Radiopharmaceutical Chemistry, Sydney, Australia 2003: S63
120. Karimi F, Langstrom B. Synthesis of 3[2S)-azetidin-2-ylmethoxy]-5-[11C]-methylpyridine, an analogue of A-85380, via a Stille coupling. J Labelled Comp Radiopharm 2002; 45: 423-434.
121. 11C]methyl-A-85380 as an imaging agent for PET investigations of brain nicotinic acetylcholine receptors. J Nucl Med 2004; 45: 878-84.
122. 11C]metanicotine) as a nicotinic receptor radioligand. Nucl Med Biol 2000; 27: 415-8.
123. 18F-Nifzetidine. Neuroimage 2004; 22: T124.
124. 18F]NicFP): A potential a4b2 nicotinic acetylcholine receptor radioligand for PET. J Labelled Comp Radiopharm 2003; 46: 1261-8.
125. Debruyne D, Sobrio F, Hinschberger A, Camsonne R, Coquerel A, Barre L. Short-term pharmacokinetics and brain distribution of mecamylamine as a preliminary to carbon-11 labeling for nicotinic receptor investigation. J Pharm Sci 2003; 92: 1051-7.
126. Ding YS, Volkow ND, Logan J, Garza V, Pappas N, King P, et al. Occupancy of brain nicotinic acetylcholine receptors by nicotine doses equivalent to those obtained when smoking a cigarette. Synapse 2000; 35: 234-7.
127. Kassiou M, Bottlaender M, Loc'h C, Dolle F, Musachio JL, Coulon C, et al. Pharmacological evaluation of a Br-76 analog of epibatidine: a potent ligand for studying brain nicotinic acetylcholine receptors. Synapse 2002; 45: 95-104.
128. Patt JT, Spang JE, Westera G, Buck A, Schubiger PA. Synthesis and in vivo studies of [C-11]N-methylepibatidine: comparison of the stereoisomers. Nucl Med Biol 1999; 26: 165-73.
129. Patt JT, Spang JE, Buck A, Cristina H, Arras M, Schubiger PA, et al. Synthesis and in vivo studies of the stereoisomers of N-[11C]methyl-homoepibatidine. NuclMed Biol 2001; 28: 645-55.
130. Spang JE, Patt JT, Westera G, Schubiger PA. Comparison of N-[11C]methyl-norchloroepibatidine and N-[11C]methyl-2-(2-pyridyl)-7-azabicyclo[2.2.1]heptane with N-[11C]methyl-epibatidine in small animal PET studies. Nucl Med Biol 2000; 27: 239-47.
131. Huang Y, Zhu Z, Narendran R, Guo N, Ekelund J, Guillin O, et al. Pharmacological evaluation of [C-11]2-[3-(6-chloro-5-phenl) pyridinyl)]-7-methyl-7-aza-bicyclo[2. 2. 1]heptane, a new pet radioligand for the nicotinic acetylcholine receptors. Neuroimage 2004; 22: T113.
132. Berg DK, Conroy WG. Nicotinic alpha 7 receptors: synaptic options and downstream signaling in neurons. J Neurobiol 2002; 53: 512-23.
133. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proceedings of the National Academy of Science of the United States of America 1997; 94: 587-92.
134. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995; 38: 22-23.
135. Martin-Ruiz C, Court J, Lee M, Piggott M, Johnson M, Ballard C, et al. Nicotinic receptors in dementia of Alzheimer, Lewy body and vascular types. Acta Neurol Scand Suppl 2000; 176: 34-41.
136. Martin-Ruiz CM, Haroutunian VH, Long P, Young AH, Davis KL, Perry EK, et al. Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. Biol Psychiatry 2003; 54: 1222-33.
137. Nagele RG, D'Andrea MR, Anderson WJ, Wang HY. Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 2002; 110: 199-211.
138. Song P, Sekhon HS, Jia Y, Keller JA, Blusztajn JK, Mark GP, et al. Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res 2003; 63: 214-21.
139. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003; 421: 384-8.
140. 3H]-methyllycaconitine in the mouse brain. Eur J Neurosci 1999; 11: 2689-96.
141. Hellstrom-Lindahl E, Court JA. Nicotinic acetylcholine receptors during prenatal development and brain pathology in human aging. Behav Brain Res 2000; 113: 159-68.
142. Gotti C, Carbonnelle E, Moretti M, Zwart R, Clementi F. Drugs selective for nicotinic receptor subtypes: a real possibility or a dream? Behav Brain Res 2000; 113: 183-92.
143. Macor JE, Mullen G, Verhoest P, Sampognaro A, Shepardson B, Mack RA. A Chiral Synthesis of (-)-Spiro[1-azabicyclo[2.2.2] octane-3,5′- oxazolidin-2′-one]: A Conformationally Restricted Analogue of Acetylcholine That Is a Potent and Selective a7 Nicotinic Receptor Agonist. J Org Chem 2004; 69: 6493-5.
144. Meyer EM, Tay ET, Papke RL, Meyers C, Huang GL, de Fiebre CM. 3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat α7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res 1997; 768: 49-56.
145. Mullen G, Napier J, Balestra M, DeCory T, Hale G, Macor J, et al. (-)-Spiro[1-azabicyclo[2.2.2]octane-3,5′-oxazolidin-2′-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor. J Med Chem 2000; 43: 4045-50.
146. Phillips E. α7-Selective compounds as novel potential therapeutics for CNS diseases. Abstracts of Papers 228th ACS National Meeting, Philadelphia, PA, US, August 22-26 2004; MEDI-024.
147. Phillips E Preparation of (2′R)-5′-(3-furanyl)spiro[1-azabicyclo[2.2. 2]octane]-3,2′(3′H)-furo[2,3-b]pyridine as a nicotinic acetylcholine receptor ligand. 2003, US Patent Application 2003/0018042 A1
148. Pomper MG, Phillips E, Fan H, McCarthy DJ, Keith RA, Gordon JC, et al. Synthesis and Biodistribution of Radiolabeled α7 Nicotinic Acetylcholine Receptor Ligands. J Nucl Med 2005; 46: 326-34.
149. Sullivan JP, Decker MW, Brioni JD, Donnelly-Roberts D, Anderson DJ, Bannon AW, et al. (+/-)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J Pharmacol Exp Ther 1994; 271: 624-31.
150. Horti A, Scheffel U, Stathis M, Finley P, Ravert HT, London ED, et al. Fluorine-18-FPH for PET imaging of nicotinic acetylcholine receptors. J Nucl Med 1997; 38: 1260-5.
151. Dannals RF, Ravert HT, Wilson AA, Wagner HN Jr. Special problems associated with the synthesis of high specific activity carbon-11 labeled radiotracers. New Trends Radiopharm. Synth., Qual Assur Regul Control, [Proc Am Chem Soc Int Symp] 1991: 21-30.
152. Dannals RF, Ravert HT, Wilson AA, Wagner HN Jr. Synthesis of high specific activity carbon-11 labeled tracers for neuroreceptor studies. Synth Appl Isot Labelled Cpd 1988; Proc Int Symp 1989; 457-64.
153. Allayarov SR, Gordon DA, Kim IP. Radiolysis of n-perfluoroalkanes and polytetrafluoroethylene. J Fluor Chem 1999; 96: 61-64.
154. Tsuji A, Tamai II. Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv Drug Deliv Rev 1999; 36: 277-290.
155. Smith DA, Jones BC, Walker DK. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med Res Rev 1996; 16: 243-66
156. Testa B, Crivori P, Reist M, Carrupt PA. The influence of lipophilicity on the pharmacokinetic behavior of drugs: concepts and examples. Perspectives Drug Discovery Des 2000; 19: 179-211
157. Tsuji A. Small Molecular Drug Transfer across the Blood-Brain Barrier via Carrier-Mediated Transport Systems. NeuroRx 2005; 2: 54-62.
158. Armijo JA, Shushtarian M, Valdizan EM, Cuadrado A, de las Cuevas I, Adin J. Ion channels and epilepsy. Curr Pharm Des 2005; 11(15): 1975-2003.
159. Shinotoh H, Fukushi K, Nagatsuka S, Irie T. Acetylcholinesterase imaging: its use in therapy evaluation and drug design. Curr Pharm Des 2004; 10(13): 1505-17.
160. Villarroya M, Garcia AG, Marco JL. New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer's disease. Curr Pharm Des 2004; 10(25): 3177-84.